Alexandra Traverse-Glehen Selected Research

Vinblastine (Vinblastine Sulfate)

11/2023	Phase 2 LYSA study of prednisone, vinblastine, doxorubicin, bendamustine for untreated older Hodgkin lymphoma patients.
10/2023	Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
1/2019	PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alexandra Traverse-Glehen Research Topics

Disease

26	Lymphoma (Lymphomas) 03/2024 - 03/2005
18	Neoplasms (Cancer) 12/2023 - 09/2004
7	B-Cell Lymphoma (Lymphoma, B Cell) 12/2023 - 03/2005
7	Hodgkin Disease (Hodgkin's Disease) 11/2023 - 03/2013
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2021 - 01/2018
3	Disease Progression 10/2022 - 01/2003
3	Neoplasm Metastasis (Metastasis) 02/2022 - 10/2020
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 05/2020 - 02/2016
3	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 05/2018 - 03/2005
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2017 - 03/2005
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2016
2	Inflammation (Inflammations) 01/2022 - 05/2020
2	Multiple Myeloma 01/2022 - 01/2017
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2021 - 01/2016
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 05/2020 - 01/2020
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 04/2011
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2016 - 04/2011
2	Infections 01/2016 - 02/2012
2	Cytopenia 08/2014 - 02/2003
1	Residual Neoplasm 03/2024
1	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 07/2023
1	Familial primary gastric lymphoma 02/2023
1	Mucormycosis 01/2023
1	Sclerosis 10/2022
1	Macrophage Activation Syndrome 10/2022
1	Cerebellar Ataxia (Dysmetria) 01/2022
1	Ataxia (Dyssynergia) 01/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Histiocytosis 12/2021
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 01/2021
1	Infertility (Sterility) 01/2019
1	Fever (Fevers) 02/2017
1	Lymphadenopathy 02/2017
1	Pathologic Complete Response 01/2017
1	Plasmacytoma 01/2017
1	Necrosis 05/2016
1	Malignant Mesothelioma 04/2016
1	Melanoma (Melanoma, Malignant) 01/2016

Drug/Important Bio-Agent (IBA)

9	Rituximab (Mabthera)FDA Link 03/2024 - 03/2010
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2010
5	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 01/2019
5	AntigensIBA 01/2019 - 04/2005
3	Bendamustine Hydrochloride FDA Link 03/2024 - 12/2018
3	Prednisone (Sone)FDA LinkGeneric 11/2023 - 01/2019
3	Vinblastine (Vinblastine Sulfate)FDA Link 11/2023 - 01/2019
3	Brentuximab VedotinIBA 10/2023 - 06/2018
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 07/2023 - 01/2019
3	CytokinesIBA 10/2022 - 05/2003
3	ParaffinIBA 01/2018 - 01/2014
3	Immunoglobulins (Immunoglobulin)IBA 04/2016 - 03/2005
2	Dacarbazine (DIC)FDA LinkGeneric 10/2023 - 01/2019
2	RNA (Ribonucleic Acid)IBA 02/2023 - 12/2022
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2020
2	Dihydrotachysterol (AT 10)IBA 02/2022 - 10/2019
2	Netrin-1IBA 01/2022 - 02/2016
2	LigandsIBA 01/2022 - 02/2016
2	ParaproteinsIBA 12/2021 - 03/2005
2	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 01/2019
2	Toll-Like Receptors (Toll-Like Receptor)IBA 05/2018 - 01/2016
2	Formaldehyde (Formol)FDA Link 01/2018 - 01/2018
2	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 01/2018 - 01/2003
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023
1	Prednisolone (Predate)FDA LinkGeneric 07/2023
1	CarcinogensIBA 02/2023
1	VaccinesIBA 02/2023
1	PromegaIBA 01/2023
1	Nucleic AcidsIBA 01/2023
1	Galectin 1 (LGALS1)IBA 10/2022
1	SuspensionsIBA 03/2022
1	Granzymes (Granzyme)IBA 02/2022
1	AntibodiesIBA 01/2022
1	IgKIBA 01/2022
1	Epidermal Growth Factor (EGF)IBA 01/2022
1	NetrinsIBA 01/2022
1	HMGA ProteinsIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	B7-H1 AntigenIBA 01/2021
1	AerosolsIBA 10/2020
1	cyclopropapyrroloindoleIBA 10/2020
1	FibrinIBA 05/2020
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 01/2019
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2019
1	Etoposide (VP 16)FDA LinkGeneric 01/2019
1	Procarbazine (Matulane)FDA Link 01/2019
1	Biomarkers (Surrogate Marker)IBA 10/2018
1	Co-Repressor ProteinsIBA 10/2017
1	Cyclin D3IBA 01/2017
1	Interleukin-8 (Interleukin 8)IBA 01/2016

Therapy/Procedure

9	Therapeutics 11/2023 - 09/2004
8	Drug Therapy (Chemotherapy) 12/2023 - 11/2011
4	Splenectomy 12/2018 - 02/2003
3	Radiotherapy 01/2017 - 11/2011
2	Breast Implants (Breast Implant) 05/2020 - 01/2020
2	Stem Cell Transplantation 04/2020 - 06/2018
2	Immunotherapy 12/2018 - 05/2003
1	Lymph Node Excision (Lymph Node Dissection) 12/2022
1	Palliative Care (Palliative Therapy) 10/2020
1	Induction Chemotherapy 01/2018
1	Transplantation 01/2017
1	Aftercare (After-Treatment) 05/2016